On March 16, 2022 Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, reported the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging (Press release, Catalent, MAR 16, 2022, https://www.catalent.com/catalent-news/catalent-biologics-completes-30-million-project-for-biopharmaceutical-development-and-drug-product-manufacturing-in-limoges-france/ [SID1234610167]). The site will further expand Catalent Biologics’ global network, with early phase integrated clinical development through to clinical supply services and small-scale commercial manufacturing, allowing seamless tech transfer of projects as they progress to late-stage and larger-scale commercial supply from other Catalent manufacturing facilities in Europe and North America.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The project has seen a complete modernization of the Limoges site, to handle large molecule programs, with additional capacity for small molecule injectable dosage form development. A new small-to-mid-scale flexible filling line has been installed, capable of handling vials, syringes or cartridges under barrier isolator technology, and enhancements have been made to analytical and quality control laboratories, supporting clinical packaging, cold storage, and regulatory capabilities. It is envisaged that the expansion will create up to 80 additional jobs at the site.
"This investment has transformed the Limoges site into a world-class facility to support the development of early phase and small-scale commercial biologic drugs, and offers customers integrated services to accelerate programs towards and through the clinic, and ultimately to market. Even prior to completion, multiple clinical and commercial customers have already signed contracts for programs to be undertaken at the site," commented Mike Riley, Catalent’s President, Biotherapeutics. "Limoges will now work closely with other Catalent facilities in Europe and the U.S. to provide globally integrated solutions for a range of therapies."
With over 40 years of experience and expertise in supplying life-saving injectable medicines, Catalent Biologics’ approximately 56,000 square-foot (5,200 square-meter) Limoges site currently employs over 170 staff.